Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Non-Current Deffered Revenue (2020 - 2021)

Ensysce Biosciences (ENSC) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $2.0 million as the latest value for Q1 2021.

  • On a quarterly basis, Non-Current Deffered Revenue fell 71.43% to $2.0 million in Q1 2021 year-over-year; TTM through Mar 2021 was $2.0 million, a 71.43% decrease, with the full-year FY2020 number at $6.8 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $2.0 million for Q1 2021 at Ensysce Biosciences, down from $6.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $7.0 million in Q1 2020 to a low of $2.0 million in Q1 2021.